Open AccessVenetoclax Combination Improves Outcomes for Patients With Mutated AML
Author(s) -
Mark L. Fuerst
Publication year - 2021
Publication title -
oncology times
Language(s) - English
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000732968.10216.e6
Subject(s) - venetoclax , azacitidine , medicine , idh1 , oncology , myeloid leukemia , chemotherapy , hypomethylating agent , leukemia , mutation , biology , genetics , chronic lymphocytic leukemia , gene expression , dna methylation , gene